JACKSON — Mississippi will receive $532,675 part of a $35 million settlement with a Pfizer Inc. subsidiary over the marketing of an organ-transplant drug.
Mississippi and 41 other states are involved in the settlement with Pfizer, the parent company of Wyeth Pharmaceuticals Inc. The deal resolves allegations Wyeth misrepresented the uses of the drug Rapamune.
A statement from Mississippi Attorney General Jim Hood says “state consumer protection laws were violated by misrepresentation of the uses and benefits of Rapamune.”
Rapamune was approved to help prevent the rejection of kidney transplants. The states alleged the company promoted it to doctors for uses following other organ transplants.
New York-based Pfizer says in a statement the alleged activity occurred before it acquired Wyeth. Pfizer didn’t admit wrongdoing or liability as part of the settlement.